Crescent Biopharma Advances CR-001 Trials with Chemotherapy Combinations, ADC Partnerships

  • Crescent Biopharma enrolling patients in standard-of-care chemotherapy combination cohorts for its Phase 1/2 ASCEND trial of CR-001, a PD-1 x VEGF bispecific antibody.
  • Initial monotherapy data from ASCEND expected in Q1 2027, with combination data mid-2027.
  • CR-001 being evaluated in multiple ADC combination studies with Kelun-Biotech, including sacituzumab tirumotecan (sac-TMT).
  • Phase 1/2 APOLLO trial of CR-002, a PD-L1-targeted ADC, set to commence dosing this quarter.
  • Phase 1/2 trial of CR-003 (SKB105), an ITGB6-targeted ADC, ongoing in China with initial data expected in Q1 2027.

Crescent Biopharma is accelerating its clinical pipeline with a focus on combination therapies, leveraging its PD-1 x VEGF bispecific antibody CR-001 alongside chemotherapy and ADCs. The company's strategic partnerships with Kelun-Biotech and Paragon Labs are central to its efforts to differentiate CR-001 as a next-generation immuno-oncology backbone. With over 2,000 patients expected to be dosed across its portfolio by mid-2027, Crescent is positioning itself for multiple pivotal readouts that could shape its long-term competitive stance in oncology.

Clinical Data Timing
Whether Crescent can deliver on its timeline for initial monotherapy and combination data from the ASCEND trial in Q1 and mid-2027, respectively.
Regulatory Pathway
The pace at which Crescent advances CR-001 into Phase 3 studies, contingent on ASCEND data and regulatory interactions.
ADC Combination Strategy
How the integration of CR-001 with multiple ADCs, particularly sac-TMT, will impact its positioning in the immuno-oncology landscape.